Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
| Condition | Asthma |
|---|---|
| Phase | Phase 4 |
| Sponsor | AstraZeneca |
| Status | Completed |
| Enrollment | 286 participants |
| Interventions | Tezepelumab |
| Start date | Apr 29, 2022 |
| Completion date | Oct 1, 2025 |
| Results posted | Jul 16, 2026 |
Summary
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Annualized Asthma Exacerbation Rate (AAER)
| Tezepelumab | 2.8783 ± 2.69 Adjusted rate (exacerbations per year) |
|---|---|
| Tezepelumab | 0.8665 ± 0.71 Adjusted rate (exacerbations per year) |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.